Trial Information - Phase II
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above
Protocol ID: SGN35-015
Sponsor: Seatlte Genetics. Inc.
Status: STAR TRIAL
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
